Opioid Addiction – Unmet Need – Detailed, Expanded Analysis (US/EU)
The few currently available pharmacological treatments for opioid addiction fall into one of two categories: substitution therapies or abstinent therapies. Substitution therapies (i.e., methadone, buprenorphine, and buprenorphine / naloxone combination) prevent a patient from experiencing withdrawal symptoms but allow the patient to still experience a limited “high” without taking any illicit opioids. Abstinent therapies (i.e., naltrexone) block the euphoric effect of opioids if a patient attempts to take an illicit opioid. However, all of these drugs are associated with clinical shortcomings in efficacy, safety, and/or delivery, creating opportunities for new and improved alternatives. This report examines physicians’ key treatment drivers and analyzes the greatest areas of unmet treatment need and thereby the opportunities in this space.
Questions Answered
- What are the treatment drivers and goals for opioid addiction?
- Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do buprenorphine-containing therapies (e.g., Suboxone Film, Sublocade) perform on key treatment drivers and goals for opioid addiction?
- What are the prevailing areas of unmet need and opportunity in the treatment of opioid addiction?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European psychiatrists for a hypothetical new opioid addiction drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European psychiatrists fielded in November 2018
Key companies: Indivior, Orexo, Braeburn Pharmaceuticals, Camurus
Key drugs: Suboxone Film, Subutex, Sublocade, Zubsolv, methadone, naltrexone
Key metrics included:
- Target Product Profile (TPP) simulator based on conjoint analysis methodology.
- Stated versus derived importance of product attributes on prescribing behavior.
- Assessment of current drug performance against treatment drivers and goals.
- Physician perceptions of unmet needs in the indication and related indications.
- Analysis of remaining drug development opportunities.
Product Description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Table of contents
- Opioid Addiction - Unmet Need - Detailed, Expanded Analysis (US/EU)
- Introduction
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Psychiatrists' Prescribing Decisions in Opioid Addiction
- Importance of Efficacy Attributes to Prescribing Decisions in Opioid Addiction: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Opioid Addiction: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Opioid Addiction: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Opioid Addiction: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Opioid Addiction: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Opioid Addiction: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Opioid Addiction: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Opioid Addiction: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Opioid Addiction: United States
- Overall Performance of Key Therapies for Opioid Addiction: Europe
- Mean Overall Performance of Key Therapies for Opioid Addiction: United States and Europe
- Relative Performance of Key Therapies for Opioid Addiction Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Opioid Addiction Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Opioid Addiction Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for Opioid Addiction Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Opioid Addiction Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Opioid Addiction Across Select Convenience of Administration Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Opioid Addiction
- Surveyed Psychiatristsu2019 Satisfaction with the Performance of Key Therapies for Opioid Addiction on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Psychiatristsu2019 Satisfaction with the Performance of Key Therapies for Opioid Addiction on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Psychiatristsu2019 Ascribed Level of Unmet Need Across Key Efficacy Attributes in Opioid Addiction: United States
- Surveyed Psychiatristsu2019 Ascribed Level of Unmet Need Across Key Efficacy Attributes in Opioid Addiction: Europe
- Surveyed Psychiatristsu2019 Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Opioid Addiction: United States
- Surveyed Psychiatristsu2019 Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Opioid Addiction: Europe
- Surveyed Psychiatristsu2019 Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Opioid Addiction: United States
- Surveyed Psychiatristsu2019 Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Opioid Addiction: Europe
- Key Findings: Unmet Need in Opioid Addiction and Related Indications
- Surveyed Psychiatristsu2019 Ascribed Level of Unmet Need in Opioid Addiction and Related Indications: United States
- Surveyed Psychiatristsu2019 Ascribed Level of Unmet Need in Opioid Addiction and Related Indications: Europe
- Opportunity Analysis
- Target Product Profiles
- Appendix
- 2019 TPP Simulator for Opioid Addiction
Niyati Khetarpal, M.Sc., M.B.A., Ph.D., is a senior analyst on the CNS/Ophthalmology Disorders team at Clarivate. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Dr. Khetarpal obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology in New Delhi, where she conducted research on Dengue virus vaccines. In 2014, she received a Fulbright-Nehru doctoral scholarship for her research on Dengue and West Nile virus envelope proteins.